JINDALEE RESOURCES LIMITED (ASX: JRL) (Jindalee, the Company) is an Australian exploration company with Tier 1 lithium deposits in its portfolio in the United States. The Company’s core goals are to discover world-class mineral deposits and generate shareholder wealth. The United States is one of the largest marketplaces for lithium demand, and Jindalee is a leading company committed to help meet future demand. The Company is focussing efforts into developing its McDermitt lithium deposit. Jindalee Resources was listed on the Australian Securities Exchange (ASX) on 11th July 2002 and raised AUD 2.70 million. Now, it is a pure-play United States lithium company. Jindalee’s Projects: In June 2018, the Company acquired McDermitt and Clayton North, two lithium sediment projects in the United States. Both projects are 100% owned by HiTech Minerals Inc., a wholly owned, US-based subsidiary of Jindalee. Several factors attracted the Company’s interest in these projects including: Potenti...
Roquefort Therapeutics PLC (LSE: ROQ) And Randox Laboratories Strike Exclusive License Agreement For Medical Diagnostics
Roquefort Therapeutics PLC (LSE: ROQ, OTCQB: ROQAF), a cancer-focused biotechnology company, has made a significant announcement recently. The Company has signed an EXCLUSIVE LICENSING AND ROYALTY AGREEMENT with Randox Laboratories Ltd., a global leader in medical diagnostics. The agreement (“Randox Licence Agreement”) pertains to Roquefort’s Midkine antibody portfolio and is limited to medical diagnostics. As per the Randox Licence Agreement, Roquefort Therapeutics has granted Randox an exclusive worldwide (except Japan) license to use its Midkine antibodies in medical diagnostics. This license agreement is valid for ten years. The two companies will work together on a combined research programme to identify new cancer diagnostics that will be treatable with Roquefort’s Midkine therapeutics. This collaborative effort aims to leverage the strengths of both companies to develop innovative diagnostic solutions for cancer patients. The agreement’s commercial terms rema...